Viridian Therapeutics (VRDN) Competitors

Viridian Therapeutics logo
$29.80 -1.07 (-3.47%)
Closing price 04:00 PM Eastern
Extended Trading
$29.82 +0.02 (+0.07%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

VRDN vs. SMMT, KYMR, BMRN, PCVX, and IBRX

Should you buy Viridian Therapeutics stock or one of its competitors? Viridian Therapeutics's main competitors and comparable companies include Summit Therapeutics (SMMT), Kymera Therapeutics (KYMR), BioMarin Pharmaceutical (BMRN), Vaxcyte (PCVX), and ImmunityBio (IBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Viridian Therapeutics compare to Summit Therapeutics?

Viridian Therapeutics (NASDAQ:VRDN) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

In the previous week, Viridian Therapeutics had 1 more articles in the media than Summit Therapeutics. MarketBeat recorded 9 mentions for Viridian Therapeutics and 8 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.99 beat Viridian Therapeutics' score of 0.76 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Viridian Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Summit Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Viridian Therapeutics presently has a consensus target price of $41.00, suggesting a potential upside of 32.82%. Summit Therapeutics has a consensus target price of $28.61, suggesting a potential upside of 102.17%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Viridian Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viridian Therapeutics
1 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.83
Summit Therapeutics
1 Sell rating(s)
7 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.58

Viridian Therapeutics has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viridian Therapeutics$26.31M133.24-$342.60M-$3.84N/A
Summit TherapeuticsN/AN/A-$1.08B-$1.07N/A

4.6% of Summit Therapeutics shares are owned by institutional investors. 2.4% of Viridian Therapeutics shares are owned by insiders. Comparatively, 81.8% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summit Therapeutics has a net margin of 0.00% compared to Viridian Therapeutics' net margin of -1,620.79%. Viridian Therapeutics' return on equity of -79.67% beat Summit Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Viridian Therapeutics-1,620.79% -79.67% -44.72%
Summit Therapeutics N/A -138.82%-117.11%

Viridian Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.49, indicating that its stock price is 249% less volatile than the broader market.

Summary

Viridian Therapeutics beats Summit Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Viridian Therapeutics compare to Kymera Therapeutics?

Viridian Therapeutics (NASDAQ:VRDN) and Kymera Therapeutics (NASDAQ:KYMR) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

In the previous week, Viridian Therapeutics had 5 more articles in the media than Kymera Therapeutics. MarketBeat recorded 9 mentions for Viridian Therapeutics and 4 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.07 beat Viridian Therapeutics' score of 0.76 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Viridian Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Kymera Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Kymera Therapeutics has a net margin of -285.33% compared to Viridian Therapeutics' net margin of -1,620.79%. Kymera Therapeutics' return on equity of -22.39% beat Viridian Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Viridian Therapeutics-1,620.79% -79.67% -44.72%
Kymera Therapeutics -285.33%-22.39%-20.48%

Viridian Therapeutics presently has a consensus price target of $41.00, suggesting a potential upside of 32.82%. Kymera Therapeutics has a consensus price target of $139.16, suggesting a potential upside of 9.09%. Given Viridian Therapeutics' higher probable upside, research analysts clearly believe Viridian Therapeutics is more favorable than Kymera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viridian Therapeutics
1 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.83
Kymera Therapeutics
1 Sell rating(s)
2 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.89

Kymera Therapeutics has higher revenue and earnings than Viridian Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viridian Therapeutics$26.31M133.24-$342.60M-$3.84N/A
Kymera Therapeutics$102.24M106.53-$311.35M-$3.62N/A

Viridian Therapeutics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market.

Summary

Kymera Therapeutics beats Viridian Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Viridian Therapeutics compare to BioMarin Pharmaceutical?

Viridian Therapeutics (NASDAQ:VRDN) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

Viridian Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market.

BioMarin Pharmaceutical has higher revenue and earnings than Viridian Therapeutics. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viridian Therapeutics$26.31M133.24-$342.60M-$3.84N/A
BioMarin Pharmaceutical$3.22B3.44$348.90M-$0.10N/A

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 2.4% of Viridian Therapeutics shares are held by insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Viridian Therapeutics and Viridian Therapeutics both had 9 articles in the media. Viridian Therapeutics' average media sentiment score of 0.76 beat BioMarin Pharmaceutical's score of 0.35 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Viridian Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
BioMarin Pharmaceutical
1 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Viridian Therapeutics currently has a consensus price target of $41.00, indicating a potential upside of 32.82%. BioMarin Pharmaceutical has a consensus price target of $87.22, indicating a potential upside of 52.40%. Given BioMarin Pharmaceutical's higher possible upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Viridian Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viridian Therapeutics
1 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.83
BioMarin Pharmaceutical
1 Sell rating(s)
6 Hold rating(s)
15 Buy rating(s)
3 Strong Buy rating(s)
2.80

BioMarin Pharmaceutical has a net margin of -0.52% compared to Viridian Therapeutics' net margin of -1,620.79%. BioMarin Pharmaceutical's return on equity of 5.58% beat Viridian Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Viridian Therapeutics-1,620.79% -79.67% -44.72%
BioMarin Pharmaceutical -0.52%5.58%3.51%

Summary

BioMarin Pharmaceutical beats Viridian Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Viridian Therapeutics compare to Vaxcyte?

Viridian Therapeutics (NASDAQ:VRDN) and Vaxcyte (NASDAQ:PCVX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

In the previous week, Vaxcyte had 3 more articles in the media than Viridian Therapeutics. MarketBeat recorded 12 mentions for Vaxcyte and 9 mentions for Viridian Therapeutics. Vaxcyte's average media sentiment score of 0.88 beat Viridian Therapeutics' score of 0.76 indicating that Vaxcyte is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Viridian Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Vaxcyte
6 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Viridian Therapeutics has higher revenue and earnings than Vaxcyte. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viridian Therapeutics$26.31M133.24-$342.60M-$3.84N/A
VaxcyteN/AN/A-$766.63M-$8.06N/A

Vaxcyte has a net margin of 0.00% compared to Viridian Therapeutics' net margin of -1,620.79%. Vaxcyte's return on equity of -42.04% beat Viridian Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Viridian Therapeutics-1,620.79% -79.67% -44.72%
Vaxcyte N/A -42.04%-36.82%

Viridian Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market.

96.8% of Vaxcyte shares are held by institutional investors. 2.4% of Viridian Therapeutics shares are held by insiders. Comparatively, 3.3% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Viridian Therapeutics presently has a consensus target price of $41.00, suggesting a potential upside of 32.82%. Vaxcyte has a consensus target price of $110.50, suggesting a potential upside of 74.37%. Given Vaxcyte's higher probable upside, analysts plainly believe Vaxcyte is more favorable than Viridian Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viridian Therapeutics
1 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.83
Vaxcyte
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67

Summary

Vaxcyte beats Viridian Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Viridian Therapeutics compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Viridian Therapeutics (NASDAQ:VRDN) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

ImmunityBio presently has a consensus price target of $16.00, suggesting a potential upside of 165.78%. Viridian Therapeutics has a consensus price target of $41.00, suggesting a potential upside of 32.82%. Given ImmunityBio's higher possible upside, equities research analysts plainly believe ImmunityBio is more favorable than Viridian Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmunityBio
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Viridian Therapeutics
1 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.83

Viridian Therapeutics has lower revenue, but higher earnings than ImmunityBio. Viridian Therapeutics is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunityBio$113.29M56.53-$351.40M-$1.08N/A
Viridian Therapeutics$26.31M133.24-$342.60M-$3.84N/A

In the previous week, ImmunityBio had 27 more articles in the media than Viridian Therapeutics. MarketBeat recorded 36 mentions for ImmunityBio and 9 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 0.76 beat ImmunityBio's score of -0.18 indicating that Viridian Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ImmunityBio
3 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
8 Negative mention(s)
1 Very Negative mention(s)
Neutral
Viridian Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

8.6% of ImmunityBio shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by insiders. Comparatively, 2.4% of Viridian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ImmunityBio has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market. Comparatively, Viridian Therapeutics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

ImmunityBio has a net margin of -607.79% compared to Viridian Therapeutics' net margin of -1,620.79%. ImmunityBio's return on equity of 0.00% beat Viridian Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ImmunityBio-607.79% N/A -54.83%
Viridian Therapeutics -1,620.79%-79.67%-44.72%

Summary

ImmunityBio beats Viridian Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Viridian Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRDN vs. The Competition

MetricViridian TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.46B$4.07B$7.83B$11.75B
Dividend YieldN/A3.64%2.47%4.41%
P/E RatioN/A24.2434.3430.11
Price / Sales47.7614.858.005.34
Price / CashN/A21.8921.0222.34
Price / Book7.014.354.763.85
Net Income-$342.60M-$24.19M$3.52B$393.14M
7 Day Performance-1.29%-7.26%-5.34%-4.53%
1 Month Performance56.59%-4.96%-3.61%-5.86%
1 Year Performance3.58%-2.87%0.01%-7.78%

Viridian Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRDN
Viridian Therapeutics
3.72 of 5 stars
$29.80
-3.5%
$41.00
+37.6%
+7.3%$3.46B$70.85MN/A252
SMMT
Summit Therapeutics
2.6441 of 5 stars
$17.84
+9.2%
$28.61
+60.4%
-21.5%$12.93BN/AN/A265
KYMR
Kymera Therapeutics
2.0649 of 5 stars
$138.86
+5.4%
$139.16
+0.2%
+96.4%$11.63B$39.21MN/A285
BMRN
BioMarin Pharmaceutical
4.4302 of 5 stars
$57.18
+2.1%
$87.91
+53.7%
+4.6%$11.07B$3.22B32.103,221
PCVX
Vaxcyte
3.0815 of 5 stars
$67.53
+5.7%
$110.50
+63.6%
+30.1%$9.77BN/AN/A507

Related Companies and Tools


This page (NASDAQ:VRDN) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners